HPV Vaccination Schedule Recommendations

Age-Based Recommendations

The Centers for Disease Control and Prevention recommends routine HPV vaccination at age 11 or 12 years, but it can be started as early as age 9 years, with specific dosing schedules based on age at initiation: 2 doses for those starting before age 15, and 3 doses for those starting at age 15 or older 1, 2, 3
For individuals initiating vaccination before their 15th birthday, a 2-dose schedule is recommended with doses administered at 0 and 6-12 months 1, 3
For those initiating vaccination at age 15 years or older, a 3-dose schedule is recommended with doses administered at 0, 1-2, and 6 months 1, 2
Catch-up vaccination is recommended for all persons through age 26 years who are not adequately vaccinated 1, 3

Dosing Intervals and Administration

For a 2-dose schedule, the second dose should be administered 6-12 months after the first dose 1
For a 3-dose schedule, the doses should be administered at 0, 1-2, and 6 months, with minimum intervals of 4 weeks between the first and second doses and 12 weeks between the second and third doses 4, 5, 6

Special Considerations

A 3-dose schedule is recommended for individuals with certain immunocompromising conditions, regardless of age at initiation 1, 2
HPV vaccine can be administered at the same visit as other age-appropriate vaccines, using a separate syringe at a different anatomic site 4, 5

Important Clinical Considerations

No prevaccination testing is recommended before vaccination 1, 5
Cervical cancer screening recommendations have not changed for vaccinated individuals 1, 4
Vaccination is most effective when given before exposure to HPV through sexual activity 1, 2

Contraindications and Precautions

The vaccine should not be given to people with a history of immediate hypersensitivity to yeast or any vaccine component 7
Vaccination should be deferred for people with moderate or severe acute illness 7

HPV Vaccination Guidelines

Recommendations for Special Populations

The American College of Physicians recommends HPV vaccination for men who have sex with men (MSM) through age 26 years if not previously vaccinated 8
The Centers for Disease Control and Prevention suggests that while vaccination is most effective when given before exposure to HPV through sexual activity, persons who are sexually active should still be vaccinated according to age-based recommendations 8

HPV Vaccination Guidelines

Special Populations and Vaccination Administration

The American Academy of Pediatrics recommends that HPV vaccine can be administered to women with abnormal Papanicolaou test results, though they should be informed that vaccination does not protect against already acquired infections 9
Vaccination is not recommended during pregnancy; if a woman becomes pregnant during the vaccination series, subsequent doses should be postponed until after delivery 9
Breastfeeding women can safely receive the HPV vaccine 9
The Centers for Disease Control and Prevention notes that vaccination does not protect against HPV types that a person is already infected with at the time of vaccination, though it will protect against other vaccine HPV types 10
Despite vaccination, cervical cancer screening remains essential as vaccines do not protect against all oncogenic HPV types 9

Clinical Practice Points

HPV vaccination does not replace the need for cervical cancer screening; regular screening should continue according to guidelines 9

HPV Vaccine Administration for Young Adolescents

Dosing Schedule and Timing

The minimum acceptable interval between the first and second doses of HPV vaccine is 12 weeks (approximately 3 months) for individuals who start the series at any age 11
Longer intervals (closer to 12 months) between HPV vaccine doses may produce stronger immune responses than shorter intervals, as supported by the American Academy of Pediatrics 12

Important Clinical Considerations

The 2-dose schedule for 9-14 year-olds is based on robust immunogenicity data showing that younger adolescents mount stronger antibody responses than older individuals receiving 3 doses, according to the Centers for Disease Control and Prevention (CDC) guidelines 12
If the second dose is inadvertently given at age 15 or later, the series completion depends on when vaccination was initiated, not when subsequent doses are given, as recommended by the CDC 12
Patients should sit or lie down for 15 minutes after HPV vaccine administration, as syncope can occur in adolescents following injections, as advised by the American Academy of Pediatrics 11

HPV Vaccine Dosing Intervals

Age-Based Dosing Schedules

The Centers for Disease Control and Prevention recommends that if the first dose is given at age 14 years, the individual only needs 1 more dose given at least 6 months later to complete the series, regardless of when the second dose is actually administered 13
For those initiating vaccination at age 15 years or older, the Centers for Disease Control and Prevention requires a 3-dose schedule with doses at 0, 1-2, and 6 months 14

Managing Interrupted Schedules

The Centers for Disease Control and Prevention states that the vaccine series does not need to be restarted if interrupted, and if interrupted after the first dose, administer the second dose as soon as possible, ensuring the second and third doses are separated by at least 12 weeks 14, 15

Evidence Supporting Interval Recommendations

Longer intervals between doses produce stronger immune responses, with a 12-month interval between the first two doses generating more robust antibody responses than a 6-month interval, which in turn is superior to a 2-month interval, according to the American Academy of Pediatrics 13
Geometric mean antibody titers against all HPV types are significantly higher in 9-14 year-olds compared to 16-26 year-olds, supporting the two-dose schedule in younger individuals, as reported by the American Academy of Pediatrics 13

Common Pitfalls to Avoid

The Centers for Disease Control and Prevention advises against delaying vaccination waiting for "optimal" timing, as approximately 24% of adolescents report sexual intercourse by 9th grade, highlighting the importance of completing the series before sexual debut 13
The Centers for Disease Control and Prevention recommends not restarting the series if interrupted, but rather continuing from where you left off, maintaining minimum intervals, as outlined in the MMWR Recommendations and Reports 14, 15

Co-Administration with Other Vaccines

The Centers for Disease Control and Prevention states that HPV vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap and MCV4, using separate syringes at different anatomic sites, which increases the likelihood of completing all recommended adolescent vaccinations on schedule 14, 15

HPV Vaccination Completion Guidelines

Key Recommendations

The American Academy of Pediatrics recommends that the critical determining factor for HPV vaccination schedule is the age when the first dose was given, not when subsequent doses are administered, and a patient who initiated vaccination at age 14 qualifies for the 2-dose schedule regardless of the extended interval 16
The Centers for Disease Control and Prevention implies that a 2-year interval between doses is acceptable and may provide enhanced immune response, with evidence demonstrating that longer intervals between doses produce stronger antibody responses than shorter intervals 16
Approximately 24% of adolescents report sexual intercourse by 9th grade, and 58.1% by 12th grade, highlighting the importance of completing the HPV vaccination series promptly to maximize protection before potential HPV exposure 16
HPV infection incidence is nearly 60% within 2 years after sexual initiation in males, emphasizing the need for timely completion of the vaccination series 16

Cancer Prevention Benefits

The vaccination prevents anal cancer (89% HPV-associated), penile cancer (63% HPV-associated), and oropharyngeal cancer (72% HPV-associated in males), as well as genital warts (90% caused by HPV types 6 and 11), although the specific citation for this fact is not provided, the American Academy of Pediatrics and the Centers for Disease Control and Prevention recommend the vaccine for these benefits 16

Maximum Time Interval for Second HPV Vaccine Dose

Key Scheduling Principles

The Centers for Disease Control and Prevention recommends that the HPV vaccine series does not need to be restarted regardless of how long the interruption lasts between doses, and the second dose should be given as soon as possible without any upper time restriction 17
If interrupted after the first dose, administer the second dose as soon as possible, with the only requirement being that the second and third doses (if applicable) are separated by at least 12 weeks 17
The minimum interval between the first and second doses is 4 weeks, as recommended by the American Academy of Pediatrics 17, 18

Age-Based Schedule Determination

For individuals starting the HPV vaccine series at age 15 or older, the American Academy of Pediatrics recommends 3 doses at 0, 1-2, and 6 months 18
A minimum interval of 4 weeks between doses 1 and 2, and 12 weeks between doses 2 and 3 is recommended by the Centers for Disease Control and Prevention 17, 18

Clinical Implications and Common Pitfalls

Sexually active individuals should still be vaccinated according to age-based recommendations, as they are unlikely to have been infected with all vaccine HPV types, as recommended by the Centers for Disease Control and Prevention 17, 18
The vaccine does not "expire" or lose effectiveness if doses are delayed, according to the Centers for Disease Control and Prevention 17

HPV Vaccine Dosing Requirements for Immunity

Age-Based Dosing Schedule

The American Journal of Transplantation recommends that individuals initiating vaccination at age 15 or older require three doses for adequate immunity 19
All immunocompromised persons, including HIV-positive individuals and solid organ transplant recipients, require a 3-dose schedule regardless of age at initiation, as recommended by the American Journal of Transplantation 19
Seroconversion rates in transplant recipients are lower, ranging from 53-68% per HPV type, compared to immunocompetent individuals, according to the American Journal of Transplantation 19
Higher tacrolimus levels and earlier post-transplant vaccination are associated with decreased seroconversion, as reported by the American Journal of Transplantation 19
The American Journal of Transplantation also notes that cervical cancer screening should not be skipped in vaccinated individuals, as the vaccine does not protect against all oncogenic HPV types 19

HPV Vaccination for Males

Age-Based Dosing Schedule

The American Academy of Pediatrics recommends that all males receive routine HPV vaccination starting at age 11-12 years using the 9-valent HPV vaccine in a 2-dose schedule, with the second dose administered 6-12 months after the first dose 20
For males under age 15, administer 2 doses total with the second dose given 6-12 months after the first dose, as longer intervals produce stronger immune responses than shorter intervals 20
Geometric mean antibody titers are significantly higher in 9-14 year-olds compared to older age groups, supporting the two-dose schedule 20

Clinical Benefits and Rationale

The 9-valent HPV vaccine prevents genital warts, which are caused by HPV types 6 and 11 in 90% of cases 20, 21

Timing Considerations

Vaccination is most effective when given before exposure to HPV through sexual activity, and approximately 24% of adolescents report sexual intercourse by 9th grade 20, 22

Practical Administration

As of January 2017, Gardasil 9 (9vHPV) is the only HPV vaccine available in the United States, and it protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 20
The vaccine should be administered via intramuscular injection, and patients should be observed for 15 minutes post-vaccination due to the risk of syncope 22
The most common side effect is headache, which occurs in up to 50% of patients, but no severe complications have been directly linked to vaccine administration 22

Special Populations

The Centers for Disease Control and Prevention recommends routine vaccination through age 26 for men who have sex with men (MSM) and immunocompromised individuals, including HIV-positive males 21, 23

HPV Vaccination Guidelines

Key Principles

The Centers for Disease Control and Prevention recommends that if the HPV vaccine series is interrupted after any dose, the next dose should be administered as soon as possible without restarting the series 24
The American Academy of Pediatrics suggests that there is no maximum time interval between doses, and the vaccine does not lose effectiveness if doses are delayed, with longer intervals between doses producing stronger antibody responses 24

Determining the Number of Doses Needed

The American College of Physicians states that if a patient started the HPV vaccine series before age 15, they only need 2 total doses, but if they started at age 15 or older, they need 3 total doses 25

Minimum Interval Requirements

The Centers for Disease Control and Prevention recommends a minimum interval of 12 weeks between dose 2 and dose 3 for completing the HPV vaccine series 24, 25

Important Clinical Considerations

The American Academy of Family Physicians advises that no additional testing is needed before administering the remaining dose, including no HPV DNA testing, antibody testing, or Pap testing 24
The Centers for Disease Control and Prevention recommends that the vaccine will still provide protection against HPV types the patient hasn't been exposed to, even if they're sexually active 24

HPV Vaccination for Adults

Important Clinical Considerations

The American College of Physicians and other guideline societies imply that prior HPV exposure does not preclude vaccination, as history of genital warts, abnormal Pap tests, or positive HPV DNA tests are not contraindications to vaccination, according to the Annals of Internal Medicine 26, 27
The vaccine protects against HPV types not yet acquired, and most sexually active adults have been exposed to some HPV types but not all vaccine types 26, 27

Three‑Dose Gardasil Schedule

Standard Dosing Intervals

The recommended three‑dose HPV vaccine series for individuals who start vaccination at age ≥ 15 years is administered at month 0 (dose 1), 1–2 months later (dose 2), and at month 6 (dose 3) 28, 29, 30.
Dose 2 should be given 1–2 months after the first dose 28, 29, 31.
Dose 3 should be given 6 months after the first dose 28, 29, 30.

Population Requiring Three Doses

All persons who initiate the HPV vaccine series at age ≥ 15 years are required to receive the three‑dose schedule 31.

Timing and Effectiveness

Administering the vaccine before the onset of sexual activity yields the greatest protective benefit 28, 29, 31.
Even individuals who are already sexually active should receive the vaccine according to age‑based recommendations, because they are unlikely to have been infected with every HPV type covered by the vaccine 31.

Contraindications and Prior Exposure

A history of genital warts, abnormal cervical cytology, or a positive HPV DNA test does not contraindicate HPV vaccination; the vaccine still protects against HPV types not yet acquired 28, 29, 31.

HPV Vaccination Guidelines – Evidence‑Based Recommendations

Routine Vaccination Age and Schedule

Catch‑Up and Adult Vaccination (Ages 27–45)

Special Populations

Vaccine Product Information

Cancer Prevention Impact

Cervical Cancer Screening

HPV Vaccination Recommendations for Young Women

Three‑Dose Schedule Intervals

For individuals who begin HPV vaccination at age 15 years or older, a three‑dose series is required with a minimum interval of 4 weeks between dose 1 and dose 2, and 12 weeks between dose 2 and dose 3 to ensure adequate immunogenicity in this age group (CDC MMWR Recommendations and Reports) 34.

Vaccine Administration Details

The recommended HPV vaccine (Gardasil 9) is administered as a 0.5 mL intramuscular injection into the deltoid muscle for all eligible young women (CDC MMWR Recommendations and Reports) 35.

Pre‑Vaccination Testing Recommendations

No laboratory or cytologic testing (e.g., Pap smear, HPV DNA test, or HPV antibody test) is required before initiating HPV vaccination at any age, simplifying the vaccination process for all eligible individuals (CDC MMWR Recommendations and Reports) 34.

Cervavac Vaccination Recommendations for Adolescents

Dosing Schedule for Immunocompetent Youth

Administer the first dose of Cervavac at age 11 – 12 years as part of routine adolescent immunizations; a second dose given 6–12 months later completes the series (adolescents, 2‑dose schedule, series completion) 36
If the first dose is administered at age 13 – 14 years, only two total doses are required regardless of the interval to the second dose (adolescents initiating vaccination at 13–14 y, 2‑dose schedule) 37

Immunogenicity and Timing

Longer intervals between the first and second doses generate stronger antibody responses than shorter intervals (extended dosing interval, enhanced immunogenicity) 37

Rationale for Early Vaccination (Ages 11‑13)

Vaccinating before sexual debut maximizes effectiveness; about 24 % of adolescents report sexual activity by 9th grade and 58 % by 12th grade (population‑level sexual behavior, timing of vaccination) 37
Younger adolescents (9‑14 years) produce markedly higher antibody titers than older individuals receiving three doses, supporting a two‑dose schedule (age‑related immunogenicity, dose reduction) [36][37]
Approximately 40 % of individuals acquire HPV infection within two years after their first sexual intercourse (risk of infection post‑debut, urgency of early vaccination) 37

Cancer Prevention Benefits

Cervavac targets HPV types 6, 11, 16, 18, which together cause roughly 70 % of cervical cancers and 90 % of genital warts (vaccine coverage, disease burden) 36
The vaccine prevents cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers linked to these HPV types (broad oncologic protection) 36

Special Population: Immunocompromised Children

Children with immunocompromising conditions (e.g., HIV infection or use of immunosuppressive medication) require a three‑dose Cervavac schedule (0, 1‑2, 6 months) irrespective of age at initiation (immunocompromised pediatric patients, 3‑dose regimen) [38][39]

HPV Vaccination in the United States: Availability, Coverage, and Recommendations

Availability & FDA Licensing (American Academy of Pediatrics)

As of January 2017, Gardasil 9 (9‑valent HPV vaccine) is the sole HPV vaccine marketed and administered in the United States, making it the exclusive option for routine HPV immunization. 40
Prior to 2017, three HPV vaccines had been licensed in the United States:
- Cervarix (bivalent, targeting HPV 16/18) – approved for females only.
- Gardasil (quadrivalent, targeting HPV 6/11/16/18) – approved for both females and males.
- Gardasil 9 (9‑valent) – initially licensed in December 2014 and later became the only available product. 41
Gardasil 9 received progressive FDA approvals:
- December 2014 – licensed for females 9‑26 years and males 9‑15 years.
- December 2015 – extended to males 9‑26 years.
- October 2016 – FDA approved a 2‑dose schedule for persons 9‑14 years. 40
Cervarix and the original quadrivalent Gardasil were previously FDA‑approved but were no longer distributed in the United States as of January 2017. 41

HPV Type Coverage & Expected Protection (American Academy of Pediatrics)

Gardasil 9 provides the broadest serotype coverage, protecting against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58). This formulation is estimated to prevent roughly 70 % of cervical cancers attributable to HPV 16/18 plus an additional 14 % of cancers in women and 4 % in men from the five extra high‑risk types. 40
Gardasil 9 also prevents approximately 90 % of genital warts caused by HPV 6 and 11. 41
Cervarix (bivalent) protects against about 70 % of HPV‑related cancers (types 16/18) but does not cover genital warts. 40
The original quadrivalent Gardasil protects against ~70 % of HPV‑related cancers and prevents ~90 % of genital warts (types 6/11). 41

Dosing Schedules (American Academy of Pediatrics)

The recommended dosing schedule is determined by the age at the first dose, not by the specific HPV vaccine product. 40

Two‑Dose Schedule (Initiation at 9‑14 years)

Indicated for immunocompetent adolescents who receive the first dose before their 15th birthday.
Dose 1: Day 0.
Dose 2: 6‑12 months after the first dose (minimum interval 12 weeks).
Longer intervals, especially those approaching 12 months, generate stronger immune responses than shorter intervals.
Younger adolescents (9‑14 years) achieve significantly higher antibody titers than older individuals receiving three doses, supporting the two‑dose regimen. 41

Three‑Dose Schedule (Initiation at ≥15 years)

Required for all persons who start the series at age 15 years or older.
Dose 1: Day 0.
Dose 2: 1‑2 months after the first dose (minimum interval 4 weeks).
Dose 3: 6 months after the first dose (minimum interval 12 weeks after dose 2). 40

Routine and Catch‑Up Vaccination (American Academy of Pediatrics)

Routine HPV vaccination is recommended at age 11‑12 years, with the series permissible to begin as early as age 9 years. Initiating vaccination before sexual debut provides maximal protection. 41
Approximately 24 % of adolescents report having initiated sexual intercourse by ninth grade and 58 % by twelfth grade, underscoring the importance of early vaccination. 40
The vaccine remains effective in individuals who are already sexually active because it protects against HPV types not yet acquired. 41
Cervical cancer screening must continue for all women regardless of vaccination status, as current vaccines do not cover all oncogenic HPV types. 40

Clinical Considerations (American Academy of Pediatrics)

No pre‑vaccination testing (HPV DNA, serology, or Pap smear) is required.
Prior HPV exposure, a history of genital warts, abnormal Pap results, or a positive HPV test are not contraindications to vaccination.
If the vaccination series is interrupted, clinicians should continue from the point of interruption without restarting the series; the critical factor is the age at the first dose, not the timing of subsequent doses.

All bullet points are supported by citations from the referenced Pediatrics articles 40, 41.

HPV Vaccination Recommendations and Public‑Health Impact

Initiation and Routine Dosing

The recommended age to start routine HPV vaccination is 11–12 years (can be initiated as early as 9 years). 42
Individuals who receive the first dose before their 15th birthday are eligible for a 2‑dose schedule, with the second dose administered 6–12 months after the first. 42
Individuals whose first dose is given at age 15 years or older follow a 3‑dose schedule: dose 2 at 1–2 months and dose 3 at 6 months after the first dose. 42

Special Populations

All persons with immunocompromising conditions (e.g., HIV infection, solid‑organ transplant, immunosuppressive therapy) require the 3‑dose schedule regardless of age at initiation. 42

Catch‑Up Vaccination

Universal catch‑up vaccination is recommended for any person aged ≤ 26 years who has not completed the series, independent of gender, sexual orientation, or prior HPV exposure. 42
Even individuals who are already sexually active should be vaccinated because they are unlikely to have been infected with all vaccine‑covered HPV types. 42
For ages 27–45 years, catch‑up vaccination is not universally recommended; shared clinical decision‑making is advised for selected individuals. 42
Extending vaccination to age 45 years increases the number needed to vaccinate to prevent one cancer from 202 (routine program) to 6 500. 42
Factors that favor vaccination in the 27–45 year age group include new or anticipated sexual partners, men who have sex with men, immunocompromising conditions, and a limited number of lifetime sexual partners. 42
Factors that argue against vaccination in this age group include long‑term mutually monogamous relationships, prior extensive HPV exposure, and substantially reduced vaccine effectiveness due to existing infections. 42
HPV vaccines are not licensed for use in adults older than 45 years. 42

Pre‑Vaccination Testing and Contraindications

No laboratory or clinical testing (e.g., Pap smear, HPV DNA test, antibody test) is required before administering the HPV vaccine. 42
A history of genital warts is not a contraindication to vaccination. 42

Cervical Cancer Screening

Cervical cancer screening must continue for all women regardless of HPV vaccination status because the vaccine does not protect against all oncogenic HPV types. 42
HPV vaccination does not replace routine cervical cancer screening. 42

Cancer Prevention Impact

Vaccination is estimated to prevent approximately 90 % of anal cancers in the United States. 42
About 70 % of oropharyngeal cancers are preventable through HPV vaccination. 42
Between 60 % and 70 % of vaginal, vulvar, and penile cancers can be averted by vaccination. 42

Clinical Guidance

Vaccination should not be withheld from sexually active individuals, as they remain at risk for HPV types not yet acquired. 42

HPV Vaccination Recommendations and Implementation

Routine Vaccination for Children

Catch‑Up Vaccination Through Age 26

Vaccination for Adults Aged 27–45 (Shared Decision‑Making)

Special Populations

Men Who Have Sex with Men (MSM)

Pregnancy and Breastfeeding

Pre‑Vaccination Testing

Cervical Cancer Screening Post‑Vaccination

Clinical Practice Opportunities

HPV Vaccination Recommendations for Adolescents

Eligibility and Recommended Schedule

The American Cancer Society and CDC recommend that a healthy adolescent male aged 13 receive the HPV vaccine now using a 2‑dose series, with the second dose given 6–12 months after the first dose. 46

Age Window for Initiation

Routine HPV vaccination is advised for ages 11–12, can start as early as age 9, and should be offered through age 26 for those not adequately vaccinated; initiating at age 13 qualifies the individual for the more convenient 2‑dose schedule rather than a 3‑dose series. 47

Minimum and Optimal Dose Intervals

The minimum acceptable interval between the two doses is 12 weeks (≈ 3 months); intervals approaching 12 months produce stronger immune responses. (Evidence cited in the same source as the 6–12 month recommendation.) 46

Pre‑Vaccination Testing Not Required

No pre‑vaccination testing (e.g., Pap smear, HPV DNA test, or antibody testing) is needed before administering the HPV vaccine to adolescents. 46

Dose Number Determination for Immunocompetent Adolescents

Adolescents who start the series before age 15 require only two doses; a third dose is unnecessary unless the schedule is interrupted or the individual is immunocompromised. 46

Immunocompromised Schedule Exception

If the adolescent is immunocompromised (e.g., HIV‑positive, on immunosuppressive therapy, or a transplant recipient), a 3‑dose schedule (0, 1–2, and 6 months) is required regardless of age at initiation. 46

HPV Vaccination Guidance for Sexually Active Adults (Cited Evidence)

Vaccine Coverage and Effectiveness

The HPV vaccine does not protect against HPV types a person is already infected with at the time of vaccination, but it does protect against the remaining vaccine‑covered types that have not yet been acquired. (Centers for Disease Control and Prevention) 48
In sexually active adults, overall vaccine effectiveness is lower than when vaccination occurs before exposure; however, the majority of women in this age group still achieve at least partial benefit from vaccination. (Centers for Disease Control and Prevention) 48

Continued Cervical Cancer Screening

Routine cervical cancer screening (Pap smear and HPV testing) must continue regardless of vaccination status, because the vaccine does not protect against all oncogenic HPV types. (Centers for Disease Control and Prevention) 48